Article

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster

2021-05-06

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic of coronavirus disease 2019 (COVID-19) that has led to more than 3 million deaths worldwide. Safe and effective vaccines are now available, including the mRNA-1273 prototype vaccine, which encodes for the Wuhan SARS-CoV-2 spike (S) protein stabilized in the prefusion conformation by 2 proline substitutions. Thi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 07c6627c-3751-5a69-82e9-3eb34e9b47dd
DOI: 10.1101/2021.05.05.21256716

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterDOI 10.1101/2021.05.05.21256716Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.Semantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 VariantsSemantic proximity Read

Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity Read

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsSemantic proximity Read